CG Oncology, Inc.

Biological Products, (No Diagnostic Substances)·DALLAS, TX·FY end 12/31·CIK 1991792

CEO Pay Ratio

6:1

Arthur Kuan

CEO Total Comp

$11.9M

Arthur Kuan

Median Employee

—

Revenue

—

FY 2025

Net Income

-$161.0M

FY 2025

Free Cash Flow

-$132.5M

FY 2025

Net Margin

—

Insider Net (180d)

-$1.9M

0 buys / 6 sales

CEO Pay Accountability

CEO comp as % of net income

-7.41%

For every $1,000 of profit, $-74.09 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

2-year history · USD

Metric	FY 2025	FY 2024	Trend
Revenue	—	—	—
Gross Profit	—	—	—
Operating Income	-$190.8M	-$114.7M
Net Income	-$161.0M	-$88.0M
Operating CF	-$132.3M	-$78.7M
Capex	$134.0K	$234.0K
Free Cash Flow	-$132.5M	-$78.9M
Buybacks	—	—	—
Dividends	—	—	—

Gross Margin	—	—	—
Operating Margin	—	—	—
Net Margin	—	—	—
FCF Margin	—	—	—
R&D / Revenue	—	—	—
Effective Tax	—	—	—
Debt / Equity	0.00	—	—
Buybacks / FCF	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Arthur KuanChief Executive Officer	$690.0K	$3.5M	$7.4M	$414.0K	$22.0K	$11.9M
Ambaw BelletePresident and Chief Operating Officer	$537.9K	—	$4.0M	$269.0K	$40.9K	$4.8M
Vijay KasturiChief Medical Officer	$502.9K	—	$2.8M	$226.3K	$30.7K	$3.6M
Joshua F. PattersonGeneral Counsel, Chief Compliance Officer, and Secretary	$461.5K	—	$1.7M	$207.7K	$24.6K	$2.4M
Corleen RochePrior Chief Financial Officer	$288.9K	—	$2.0M	—	$28.7K	$2.3M
Robert Lapetina (PriorInterim Principal Financial and Accounting Officer)	$310.2K	—	$300.7K	$2.3K	$32.1K	$645.3K
Jim DeToreChief Financial Officer	$96.0K	—	—	—	—	$96.0K